U.S. FDA places Mersana's cancer drug trial on hold following death, Health News, ET HealthWorld
Exclusive
U.S. FDA places Mersana's cancer drug trial on hold following death
The company said the death was of a patient enrolled at the initial dose level in the dose escalation portion. The study was testing the company's XMT-2056 candidate.
Reuters
March 13, 2023, 18:45 IST
Bengaluru: Mersana Therapeutics Inc said on Monday that the U.S. drug regulator had placed an early-stage trial testing its experimental cancer drug after the death of a participant.
The company said the death was of a patient enrolled at the initial dose level in the dose escalation portion. The study was testing the company's XMT-2056 candidate.
The company is now focused on analyzing the death and "consider potential next steps for development," Chief Executive Officer Anna Protopapas said in a statement.
The company will continue to make progress with the other cancer drug candidate UpRi and XMT-1660 clinical trials.
Shares of Mersana were halted before the bell.
Follow and connect with us on Twitter, Facebook, Linkedin,
Monday, March 13, 2023 at 1:15 pm